Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725527 | 0.89 | NPC1 (0.37) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL23717786 | 0.82 | CYP1A2 (0.35) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL21859720 | 0.79 | ALDH1A1 (0.33) | HSD17B10 | |
| SCHEMBL21725528 | 0.74 | PDPK1 (0.35) | — | |
| SCHEMBL22400168 | 0.69 | PDPK1 (0.34) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL23717803 | 0.64 | PDPK1 (0.38) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL24552572 | 0.63 | PDPK1 (0.37) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL19578800 | 0.61 | PPARA (0.41) | — | |
| SCHEMBL20738344 | 0.61 | IDO1 (0.39) | NPC1RAB9A | |
| SCHEMBL2466445 | 0.61 | MEN1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | NPC1 1729/4885CYP1A2 1383/4885CYP2C9 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.